Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Study of IMM-6-415 in Participants With Advanced or Metastatic Malignancies Harboring RAS or RAF Oncogenic Mutations

NCT06208124 is registered in ClinicalTrials.gov with Immuneering Corporation as lead sponsor.

NCT NCT06208124
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06208124 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Study of IMM-6-415 in Participants With Advanced or Metastatic Malignancies Harboring RAS or RAF Oncogenic Mutations
Lead sponsor
Immuneering Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
February 27, 2024
Completion date
April 30, 2025
Enrollment
30 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor (phase 1), malignant melanoma (cutaneous), non-small cell lung cancer, pancreas adenocarcinoma